Por: ABC News Health June 29, 2023
WASHINGTON -- U.S. officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, an infused treatment that can significantly reduce dangerous bleeding problems.The Food and Drug Administration approved Roctavian for adult patients with severe cases of hemophilia A, the inherited blood-clotting disorder that can lead to bleeding after minor injuries or scrapes. It's the first gene therapy for... + full article
WPLG Local 10 USA Health June 30, 2023
WASHINGTON – U.S. officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, a $2.9 million infused treatment that can significantly reduce dangerous bleeding problems.The Food and Drug Administration approved Roctavian for... + más
Gene therapy can transform life for people with hemophilia. But some patients don’t want it. | The Boston Globe
FDA approves most expensive drug ever, $3.5 million-per-dose gene therapy for hemophilia B | CBS News
ABC News USA Business June 29, 2023
WASHINGTON -- U.S. officials on Thursday approved drugmaker BioMarin's gene therapy for the most common form of hemophilia, an infused treatment that can significantly reduce dangerous bleeding problems.The Food and Drug Administration approved Roctavian for adult patients... + más
The Boston Globe USA Business January 30, 2023
Given everything he’s been through, Bobby Wiseman says he should have been dead instead of celebrating the birth of his first grandchild several days ago.Wiseman, 51, who lives near Sacramento, was diagnosed as an infant with hemophilia, the rare genetic disease that prevents... + más
$3.5M gene therapy for hemophilia gets FDA approval | ABC News
ABC News USA Health November 23, 2022
WASHINGTON -- U.S. regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the... + más
$3.5M gene therapy for hemophilia gets FDA approval | WPLG Local 10
WPLG Local 10 USA Health November 23, 2022
WASHINGTON – U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
CBS News USA Health November 23, 2022
Washington — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
Associated Press USA Science November 23, 2022
WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less... + más
About iurex | Privacy Policy | Disclaimer |